Respiratory Syncytial Virus Clinical Trial
Official title:
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus
This is a study of molnupiravir (MK-4482) in healthy participants who have been inoculated with an experimental Respiratory Syncytial Virus (RSV) [RSV-A Memphis 37b]. It is hypothesized that treatment with the drug MK-4482 (molnupiravir) will reduce the peak viral load (PVL) in the participant compared to placebo when given either before or after RSV-A Memphis 37b inoculation.
Participants arrive at the study center for check-in between Day -3 and Day -1. Participants receive the assigned treatment beginning on Day -1. On Day 0, all participants receive viral inoculation with RSV-A Memphis 37b. All participants depart on Day 12 and follow-up is continued until Day 28. The study is designed with the following arms: - Panel A: Molupiravir Prophylaxis - in this arm, participants receive molupiravir beginning on Day -1, are incoluated with RSV-A Memphis 37b on Day 0, and continue receiving molnupiravir for a total of 5 days before switching to placebo through Day 10. - Panel B: Molupiravir Triggered Treatment - in this arm, participants receive placebo beginning on Day -1 until testing positive for RSV. Participants are inoculated with RSV-A Memphis 37b on Day 0. When participants test positive for RSV, they switch to molnupiravir for a total of 5 consecutive days before switching back to placebo through Day 10. If participants in this arm do not test positive for RSV by Day 5, they automatically switch to molnupiravir through Day 10. - Panel C: Placebo - in this arm, all participants receive placebo beginning on Day -1, are inoculated with RSV-A Memphis 37b on Day 0, and continue receiving placebo through Day 10. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04528719 -
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
|
Phase 1 | |
Terminated |
NCT02508194 -
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT06060457 -
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
|
Phase 3 | |
Terminated |
NCT01757496 -
Cough Assist in Bronchiolitis
|
N/A | |
Completed |
NCT00100373 -
RSV Challenge in Healthy Adults
|
N/A | |
Completed |
NCT03524118 -
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05572658 -
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
|
||
Recruiting |
NCT06067230 -
A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults
|
Phase 3 | |
Completed |
NCT00246480 -
RSV Disease in the Elderly
|
||
Active, not recruiting |
NCT06097299 -
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
|
Phase 2 | |
Completed |
NCT00889070 -
Respiratory Events Among Premature Infants
|
N/A | |
Unknown status |
NCT00613184 -
Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses
|
N/A | |
Active, not recruiting |
NCT05127434 -
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
|
Phase 2/Phase 3 | |
Terminated |
NCT04978337 -
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2 | |
Recruiting |
NCT06143046 -
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
|
Phase 2 | |
Active, not recruiting |
NCT05397223 -
A Study of Modified mRNA Vaccines in Healthy Adults
|
Phase 1 | |
Completed |
NCT02472548 -
A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine
|
Phase 1 | |
Completed |
NCT01734668 -
Sofia RSV FIA Field Study
|
N/A | |
Completed |
NCT01562938 -
MEDI-557 Adult Dosing
|
Phase 1 | |
Recruiting |
NCT06325657 -
A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
|
Phase 3 |